| 16.64 0.78 (4.92%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 32.6 | 1-year : | 42.17 |
| Resists | First : | 27.91 | Second : | 36.11 |
| Pivot price | 21.5  |
|||
| Supports | First : | 14.65 | Second : | 12.19 |
| MAs | MA(5) : | 16.2 |
MA(20) : | 24.27 |
| MA(100) : | 25.12 |
MA(250) : | 31.36 |
|
| MACD | MACD : | -3.5 |
Signal : | -2.6 |
| %K %D | K(14,3) : | 7.3 |
D(3) : | 7.2 |
| RSI | RSI(14): 32.4 |
|||
| 52-week | High : | 55.65 | Low : | 10.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NNNN ] has closed above bottom band by 31.9%. Bollinger Bands are 171.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 16.82 - 16.92 | 16.92 - 17 |
| Low: | 15.76 - 15.88 | 15.88 - 15.99 |
| Close: | 16.46 - 16.64 | 16.64 - 16.8 |
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Fri, 08 Aug 2025
7 healthtech scaleups to watch in Europe & UK in 2025 - Tech Funding News
Mon, 28 Apr 2025
NNNN Stock Price, News & Analysis - Stock Titan
Fri, 21 Feb 2025
Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Thu, 20 Feb 2025
Anbio Biotechnology Announces Closing of Initial Public Offering - Yahoo Finance
Thu, 20 Feb 2025
ANBIO BIOTECHNOLOGY (NNNN) Stock News & Updates - Stock Titan
Wed, 19 Feb 2025
Anbio Biotechnology’s IPO opens up 5% By Investing.com - Investing.com Nigeria
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 44 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 4.7 (%) |
| Held by Institutions | 4.9 (%) |
| Shares Short | 87 (K) |
| Shares Short P.Month | 44 (K) |
| EPS | 0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.68 |
| Profit Margin | 74 % |
| Operating Margin | 59 % |
| Return on Assets (ttm) | 14.6 % |
| Return on Equity (ttm) | 27 % |
| Qtrly Rev. Growth | 73.9 % |
| Gross Profit (p.s.) | 0.17 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | 110.93 |
| PEG Ratio | 0 |
| Price to Book value | 24.11 |
| Price to Sales | 84.43 |
| Price to Cash Flow | -108.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|